ASH 2019 – Wrap-up

Characteristics of Patients with Mantle-Cell Lymphoma and Chronic Lymphocytic Leukemia Treated with Acalabrutinib in a US Real-World Setting

ASH 2019 – Wrap-up

Insights about real-world clinical experience with new drugs, such as acalabrutinib, are highly valuable. At ASH 2019, researchers evaluated acalabrutinib use in real-world patients with mantle-cell lymphoma and chronic lymphocytic leukemia. Read More ›

Phase 3 Trial Compares Acalabrutinib plus Venetoclax with or without Obinutuzumab versus Chemoimmunotherapy as First-Line Therapy in Patients with Chronic Lymphocytic Leukemia and No del(17p) or TP53 Mutations

ASH 2019 – Wrap-up

Current treatments for chronic lymphocytic leukemia are limited by cost, toxicity, and duration of response. In the future, less toxic first-line chemotherapy-free regimens administered for a fixed duration of time may improve outcomes. Read More ›

Polatuzumab Vedotin + Obinutuzumab + Lenalidomide in Patients with Relapsed/Refractory Follicular Lymphoma

ASH 2019 – Wrap-up, ASH 2019 – CLL

Primary analysis results of a phase 1b/2 trial showed obinutuzumab + polatuzumab vedotin + lenalidomide was associated with high complete response rates and a favorable safety profile in heavily pretreated and refractory patients with follicular lymphoma. Read More ›

Zanubrutinib in Patients with Treatment-Naïve CLL/SLL with del(17p): Initial Results from Arm C of the SEQUOIA (BGB-3111-304) Trial

ASH 2019 – Wrap-up, ASH 2019 – CLL

Preliminary results of the SEQUOIA trial suggested that zanubrutinib was active and generally well tolerated in treatment-naïve patients with del(17p) chronic lymphocytic leukemia (CLL)/small lymphocytic lymphoma (SLL). Read More ›

The iR² Regimen in Relapsed/Refractory Diffuse Large B-Cell Lymphoma

ASH 2019 – Wrap-up

Diffuse large B-cell lymphoma is an aggressive type of non-Hodgkin lymphoma that is particularly difficult to treat if the patient becomes refractory to or relapses after initial treatment. Chances of survival are especially poor for people who are not eligible for stem-cell transplant. Read More ›

Lisocabtagene Maraleucel, a CD19-Directed CAR T-Cell Product, in High-Risk Patients with R/R CLL/SLL, Including Those Previously Treated with Ibrutinib

ASH 2019 – Wrap-up, ASH 2019 – Post Wrap-Up, ASH 2019 – CLL

Results from TRANSCEND CLL 004 showed chimeric antigen receptor (CAR) T-cell treatment with lisocabtagene maraleucel in heavily pretreated patients with relapsed/refractory (R/R) chronic lymphocytic leukemia (CLL)/small lymphocytic lymphoma (SLL) who had failed ibrutinib was manageable and produced durable undetectable minimal residual disease responses. Read More ›

Three-Year Update of the Phase 2 ABT-199 (Venetoclax) and Ibrutinib in Mantle-Cell Lymphoma (AIM) Study

ASH 2019 – Wrap-up, ASH 2019 – Post Wrap-Up, ASH 2019 – CLL

Results from the 3-year update of the phase 2 AIM trial confirmed the effectiveness of ibrutinib + venetoclax therapy for patients with mantle-cell lymphoma, and indicated that treatment interruption was feasible for patients in minimal residual disease–negative complete remissions. Read More ›

Bendamustine-Rituximab versus Rituximab Monotherapy for Older Patients with Nodal or Splenic Marginal Zone Lymphoma

ASH 2019 – Wrap-up, ASH 2019 – Post Wrap-Up, ASH 2019 – CLL

A large observational study showed increased first-line bendamustine-rituximab use among older patients with splenic or nodal marginal zone lymphoma was not associated with significant event-free survival or overall survival benefit versus single-agent rituximab, but led to increased toxicities and costs. Read More ›

Acalabrutinib Monotherapy in Patients with Relapsed/Refractory CLL: 42-Month Follow-Up of a Phase 2 Study

ASH 2019 – Wrap-up, ASH 2019 – Post Wrap-Up, ASH 2019 – CLL

Updated results from a phase 1/2 trial indicate that acalabrutinib monotherapy was associated with a favorable safety profile and showed antileukemic activity in patients with chronic lymphocytic leukemia (CLL)/small lymphocytic lymphoma, irrespective of high-risk genomic features. Read More ›